A Publication of Global Scientific Forum
Card image

Reviews

Use of Direct-Acting Antivirals for the Treatment of Chronic Hepatitis C Virus Infection in the Perspective of Kidney Transplantation
Authors: Wisit Cheungpasitporn, Charat Thongprayoon, Karn Wijarnpreecha, Suthanya Sornprom and Jackrapong Bruminhent

Hepatitis C virus (HCV) is more prevalent in patients with end-stage kidney disease on hemodialysis and, consequently leading to a higher prevalence of HCV infection among kidney transplant recipients than in the general population. Chronic HCV infection can contribute to increased morbidity and mortality in both the pretransplant and post-transplant settings. After transplantation, HCV infection also has adverse impacts on both patient and graft survival in kidney transplant recipients compared to those with HCV-negative including higher risks of cardiovascular disease, sepsis, and liver disease. In the recent years, notable advancement has been made in the development of oral anti-HCV agents that directly inhibit and target various HCV viral proteins with direct acting antiviral (DAA) therapies with reported excellent sustained virologic response, resulting in a paradigm shift in the management of HCV-infected patients undergoing kidney transplantation in the era of DAA therapies. In this review, we present the perspectives of use of direct-acting antivirals for the treatment of chronic hepatitis C virus infection in kidney transplant recipients.

PDF FULL TEXT
Share Now :
journal-of-basic-and-clinical-pharmacy Journal of Basic and Clinical Pharmacy, a publication of Global Scientific Research Forum, is a peer-reviewed online journal with Quarterly print on demand compilation of issues published.
Submit your Manuscript

© Journal of Basic and Clinical Pharmacy
Online since 10 September, 2012 -